HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A retraction has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sudbø, J. Search for Related Content PubMed PubMed Citation Articles by Sudbø, J.

Novel Management of Oral Cancer: A Paradigm of Predictive Oncology

Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo, Norway

REPRINT REQUESTS: Jon Sudbø, MD, DDS, PhD, Department of Medical Oncology, and Radiotherapy, The Norwegian Radium Hospital, Ullernchausséen 70, Montebello, 0310 Oslo, Norway, Telephone: + 47 22 93 58 07, Fax: + 47 22 50 85 54 Email: jon.sudbo{at}rh.uio.no

The rationale for molecular-targeted prevention of oral cancer is strong. Oral cancer is a major global threat to public health with 300,000 new cases diagnosed worldwide on an annual basis. Notably, the great morbidity and mortality rates of this devastating disease have not improved in decades. Oral cancer development is a tobacco-related multistep and multifocal process involving field carcinogenesis and intraepithelial clonal spread. Biomarkers of genomic instability, such as aneuploidy and allelic imbalance, can accurately measure the cancer risk of oral premalignant lesions or intraepithelial neoplasia (IEN). Retinoid-oral IEN studies (e.g., retinoid acid receptor-ß, p53, genetic instability, loss of heterozygosity, and cyclin D1) have advanced the overall understanding of the biology of intraepithelial carcinogenesis and preventive agent molecular mechanisms and targets, important advances for monitoring preventive interventions, assessing cancer risk, and pharmacogenomics. Clinical management of oral IEN varies from watchful waiting to complete resection, although complete resection does not prevent oral cancer in high-risk patients. New approaches, such as interventions with molecular-targeted agents and agent combinations in molecularly defined high-risk oral IEN patients, are urgently needed to reduce the devastating worldwide consequences of oral cancer.

Key Words: Carcinoma in situ • Leukoplakia, oral • Carcinoma, squamous cell • Molecular therapeutics • Cyclooxygenase-2 • Receptor, epidermal growth factor • Anti-inflammatory agents, non-steroidal

This article has been cited by other articles:

				Retraction Clin. Med. Res., October 1, 2007; 5(3): 203 - 203. [Full Text] [PDF]

				R. A. Dart and S. A. Salzman-Scott Expression of concern - sudbo j. Novel management of oral cancer: a paradigm of predictive oncology. Clin med res 2004;2:233-242. Clin. Med. Res., September 1, 2006; 4(3): 160 - 160. [Full Text] [PDF]